Media headlines about Aradigm Corporation (NASDAQ:ARDM) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aradigm Corporation earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.4248553075374 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Aradigm Corporation (ARDM) traded up $0.08 on Friday, hitting $3.62. 43,123 shares of the company were exchanged, compared to its average volume of 168,205. The company has a debt-to-equity ratio of -1.59, a current ratio of 1.65 and a quick ratio of 1.65. Aradigm Corporation has a 1-year low of $0.78 and a 1-year high of $5.68.

Aradigm Corporation (NASDAQ:ARDM) last released its earnings results on Thursday, November 2nd. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.05. The firm had revenue of $2.73 million during the quarter. Aradigm Corporation had a negative return on equity of 665.03% and a negative net margin of 118.37%. sell-side analysts forecast that Aradigm Corporation will post -0.74 earnings per share for the current fiscal year.

A number of analysts recently commented on ARDM shares. Zacks Investment Research upgraded shares of Aradigm Corporation from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research report on Tuesday, September 5th. Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $10.00 price objective (up previously from $7.50) on shares of Aradigm Corporation in a research report on Monday, September 25th.

COPYRIGHT VIOLATION WARNING: “Aradigm Corporation (ARDM) Receives Daily News Sentiment Score of 0.13” was posted by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at

About Aradigm Corporation

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

Insider Buying and Selling by Quarter for Aradigm Corporation (NASDAQ:ARDM)

Receive News & Ratings for Aradigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.